Register Login

AnaptysBio Inc (ANAB)

(90% Positive) ANAPTYSBIO, INC (ANAB) Announces Enrollment Update for trial Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 10:19 p.m.

    📋 ANAPTYSBIO, INC (ANAB) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 17:17:16

    Event Type: Clinical Trial Update

    Event Details:

    AnaptysBio Inc (ANAB) Announces Clinical Trial Update AnaptysBio Inc (ANAB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trial, best
    • Diseases/Conditions: celiac disease, class or optimized
    • Clinical Stage: clinical trial
    • Collaboration: GSK
      • targeting IL-15 or CD122 IL-15 IL-15 CD122 Broad therapeutic potential across autoimmune and inflammatory diseases 15 16 Body weight loss (carried) W e ig h t ( % o f S ta rt ) End of dosing 0 10 20 30 40 50 60 -20 -10 0 10 Body Wei L (car ied) Study Day W e ig h t (% o f S ta rt ) Cytolytic gene expression (Day 17) Expression (% of isotype) 0 50 100 150 GNLY GZMA GZMB ✱ ✱ ✱ ANB033 Forte anti-CD122 Belatacept Isotype Control ANB033 Isotype Control ****** Survival W e ig h t ( % o f S ta rt ) % R e m a in in g 0 10 20 30 40 50 60 0 10 20 30 40 50 60 70 80 90 100 Study Day P e rc e n t R e m a in in g urvival End of dosing ANB033 shows strong survival benefit and reduced cytolytic gene expression in aggressive GvHD mouse model GvHD (severe phenotype) model using human IL-15 transgenic mice that support human T cell and NK cell engraftment. 60-day study. Mice dosed 3 mg/kg BIW (belatacept 75 µg TIW) through Day 28. N=10 per group (isotype control and Belatacept) or 11 per group (test articles). *** Survival: ANB033 statistically significant vs isotype control (P<0.0001
      • targeting P1 ongoing HLA-DQ2.5 gluten peptide complex P1 ongoing SIRT6 modulator P2 ongoing Gluten tolerance Discontinued Gluten tolerance IL-15 antagonists: Clinical PoC P2 ongoing P1b PoC Lacked potency ANB033 Adapted from Dieckman et al. (2022
      • targeting upstream inflammation Isotype Control ANB033 Aspergillus-induced eosinophilia 35 C e ll C o u n t C e ll C o u n t C e ll C o u n t Eos observed lung samples shown I L -5 (% o f Is o ty p e C o n tr o l) IL-13 secretionIL-5 secretion 0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 0 0.001 0.01 0.1 1 10 100 0 25 50 75 100 125 0 I L -1 3 (% o f Is o ty p e C o n tr o l) Antibody (nM)Antibody (nM) Unstim Is oty pe 5 n M 50 n M 500 n M 0 500 1000

    🔬 Clinical Development Pipeline (ANAPTYSBIO, INC):

    Product Type Development Stage Therapeutic Area Source
    Rosnilimab DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AnaptysBio Inc
    • CIK: 0001370053
    • Ticker Symbol: ANAB
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories